NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development
NRx Pharmaceuticals (NASDAQ: NRXP) welcomed a newly signed Executive Order aimed at accelerating medical treatments for serious mental illness, including expanded access to psychedelic therapies and faster regulatory pathways. The order directs the FDA to issue priority vouchers for qualifying breakthrough therapies and encourages broader use of clinical trial data and real-world evidence, aligning with NRx’s strategy as it advances its NRX-100 drug candidate and seeks regulatory support to address severe depression, PTSD and suicidality. To view the full press release, visit https://nnw.fm/mbw06 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for…







